Five notes from the Nov. 3 report posted by NBC affiliate KULR:
1. Total third-quarter revenue was $127.7 million, up 8.6 percent from the same period last year.
2. Exparel sales were $121.9 million, a 7.2 percent increase year over year.
3. Sales for Iovera, a preoperative cold treatment, were up 55.6 percent year over year at $4.2 million.
4. Pacira saw a GAAP net income of $17.7 million.
5. The company saw Exparel sales outpace the recovery of the nonemergency surgery market, chair and CEO David Stack said.
“This underscores the growing adoption of Exparel in outpatient settings, non-elective procedures and beyond,” he said in the report. “October saw a positive shift in market dynamics, and we expect the fourth quarter to return to more robust year-over-year top-line growth.”
